Abstract | BACKGROUND: The development of potent H1-receptor antagonists that are free of adverse effects has renewed interest in their use in the treatment of asthma. METHODS: RESULTS:
Antihistamine pretreatment increased mean baseline measurements of forced expiratory volume in 1 second (FEV1) between 2.58% and 9.28% compared with placebo, which was significant for all drugs except brompheniramine and clemastine. Compared with placebo, all antihistamines provided significant protection against histamine-induced bronchoconstriction when measured as the provocation concentration required to cause a 20% fall in FEV1; terfenadine and cetirizine provided significantly greater protection than other antihistamines. Protection against histamine-induced skin wheals, measured as the slope of the log concentration-response curve, was only significant for the new drugs, terfenadine and cetirizine. There was a good correlation between the protective effect of the drugs in the skin and airways (r = 0.85; p < 0.01). No significant difference in methacholine provocation concentration required to cause a 20% fall in FEV1 values between treatments was found. CONCLUSIONS:
|
Authors | R Wood-Baker, S T Holgate |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 91
Issue 5
Pg. 1005-14
(May 1993)
ISSN: 0091-6749 [Print] United States |
PMID | 8098339
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Histamine H1 Antagonists
- Histamine
|
Topics |
- Adult
- Asthma
(drug therapy, physiopathology)
- Bronchial Provocation Tests
- Bronchoconstriction
(drug effects)
- Female
- Forced Expiratory Volume
(drug effects)
- Histamine
- Histamine H1 Antagonists
(adverse effects, pharmacology, therapeutic use)
- Humans
- Hypersensitivity, Immediate
(drug therapy)
- Male
- Middle Aged
- Single-Blind Method
- Skin Tests
|